CARA - CONSENSUS CO - Cara Therapeutics, Inc.

Cara Therapeutics, Inc. (CARA) is partnering with Vifor Pharma to promote Korsuva for the relief of dialysis-related pruritus. This daily price chart for the company, where the consensus forecast is set at 9.21, reflects a period of stagnation: legacy royalties generate revenue by inertia, but the portfolio requires updating. The business relies on outsourcing, delegating synthesis and testing to third-party contractors, which creates risks of dependency on external partners.

Cara Therapeutics, Inc. (CARA) maintains a strong reputation in developing therapies for chronic pruritus, which ensures steady interest from the professional community in the issuer's assets. The consensus price target on GURU.Markets aggregates current expectations from investment firms, allowing investors to track market sentiment dynamics in real time and assess fair equity potential without the time lags associated with traditional reporting.